Patent Application
20150144151
The present invention generally relates to hair treatment agents including a synergistic combination of selected silicones and selected complexes of acidic protein hydrolysates and basic fatty acid amidoamines.
There is a requirement to bring about further improvement in hair care products and to provide them with further advantageous properties. In particular, there is a need to provide a conditioning complex which can ideally also be used in conjunction with oxidizing agents and surfactant agents.
Environmental influences and oxidative hair treatments often lead to impaired combability of both dry and wet hair. Furthermore, gloss and moisture balance are deleteriously affected by the attacked external structure of the keratinic fibers. A further consequence of repeated treatment of keratinic fibers with surfactant and/or oxidative agents is for severe greasiness to return to the keratinic fibers and for there to be a strong tendency towards increased dandruff formation.
It is therefore desirable to reduce the side-effects of environmental influences and of oxidative and surfactant hair treatments preferably not only as early as during the oxidative or surfactant hair treatment but also after the oxidative or surfactant hair treatment without impairing the effectiveness of the oxidative or surfactant cosmetic preparation, in particular with regard to color intensity, color fastness, lightening performance or permanent-wave action, and of preventing the keratinic fibers from becoming greasy again and increased dandruff formation. Furthermore, it is also desirable, in the form of a 2-in-1 product, to combine in one application step the oxidative treatment of keratin-containing fibers, in particular human hair, with the application of effective fiber protection from environmental influences, for example UV protection.
Furthermore, other desirable features and characteristics of the present invention will become apparent from the subsequent detailed description of the invention and the appended claims, taken in conjunction with the accompanying drawings and this background of the invention.
A hair treatment agent including, relative to the weight thereof, a) at least one silicone compound in a total quantity of 0.01 to 95.0 wt. % relative to the total composition and b) at least one selected complex of an acidic protein hydrolysate and a basic fatty acid amidoamine in a total quantity of 0.01 to 10.0 wt. % relative to the total composition.
A hair treatment agent including, relative to the weight thereof, a) at least one silicone compound in a total quantity of 0.01 to 95.0 wt. % relative to the total composition and b) at least one cetearamidoethyl diethonium hydrolyzed protein in a total quantity of 0.1 to 10.0 wt. % relative to the total composition.
The following detailed description of the invention is merely exemplary in nature and is not intended to limit the invention or the application and uses of the invention. Furthermore, there is no intention to be bound by any theory presented in the preceding background of the invention or the following detailed description of the invention.
Fatty acid amidoamines and protein hydrolysates are chemical compounds which are known in principle and are likewise already used as ingredients in hair care products. Silicones are likewise known in hair treatment agents. They are frequently used for improving the properties of the hair. These known compositions are, however, incapable of satisfactorily solving the problem. Where an active substance complex is mentioned below, this phrase refers to the ingredients a) and b) which are mandatorily present in the hair treatment agents according to the invention.
The active substance complex according to the invention improves softening, improves gloss, improves moisture balance and provides protection from destructuring of keratin-containing fibers, in particular human hair, by UV radiation and very particularly it provides protection from oxidative damage, in particular it maintains hair growth, prevents hair loss and prevents the keratinic fibers from becoming greasy again and increases the washing resistance of dyed keratinic fibers. The present invention accordingly firstly provides a hair treatment agent including, relative to the weight thereof,
In a preferred embodiment of the present invention, the cosmetic agents serve to treat keratinic fibers, in particular human hair. Preferred agents according to the invention are therefore for example shampoos, hair coloring agents, conditioning agents or hair tonics.
Handle is defined as the tactile properties of a fiber assembly, wherein a person skilled in the art feels and carries out a sensory evaluation of the body and silkiness of the assembly.
Shaping is taken to mean the ability to impart a change in shape to an assembly of previously treated keratin-containing fibers, in particular human hair. In relation to hair cosmetics, it is also known as stylability.
Maintaining natural growth of keratinic fibers is taken to mean that the impact on natural hair growth caused by cosmetic treatment of the hair as mentioned above, in particular by oxidative hair treatment, is compensated and no or at most slight effects on the natural growth of the keratinic fibers with regard to growth in thickness or length and/or with regard to fullness of the hair are present.
An oxidative hair treatment is defined according to the invention as the action of an oxidative cosmetic agent containing at least one oxidizing agent in a cosmetic carrier on the hair.
The hair treatment agent including the active substance complex according to the invention is preferably used immediately before, during or after oxidative or surfactant hair treatment. For the purposes of the invention, immediately before the oxidative or surfactant hair treatment is taken to mean use directly followed by the oxidative or surfactant hair treatment, wherein the hair treatment agent including the active substance complex according to the invention has previously been rinsed off the hair or preferably left on the hair and the hair is preferably still wet.
For the purposes of the invention, after oxidative or surfactant hair treatment is taken to mean use which either directly follows the oxidative or surfactant hair treatment, wherein the hair treatment agent including the active substance complex according to the invention is applied onto the preferably still wet, towel-dry hair once the agent with an oxidative or surfactant action has been rinsed off, or onto the dry or wet hair once a number of hours or days have elapsed. In both cases, after a period of exposure of a few seconds up to 45 minutes, the hair treatment agent according to the invention may be rinsed off again or remain in its entirety on the hair.
The effect of the hair treatment agent according to the invention is manifested even during oxidative or surfactant hair treatment and surprisingly persists even after the hair treatment agent according to the invention has been thoroughly washed out.
The active substance complex according to the invention is preferably used in a cosmetic carrier. The cosmetic carriers may in particular be aqueous or aqueous-alcoholic. An aqueous cosmetic carrier includes at least 50 wt. % water. For the purposes of the present invention, aqueous-alcoholic cosmetic carriers should be taken to be aqueous solutions including 3 to 70 wt. % of a C1-C6 alcohol, in particular methanol, ethanol or propanol, isopropanol, butanol, isobutanol, tert.-butanol, n-pentanol, iso-pentanols, n-hexanol, iso-hexanols, glycol, glycerol, 1,2-pentanediol, 1,5-pentanediol, 1,2-hexanediol or 1,6-hexanediol. The agents according to the invention may additionally include further organic solvents, such as for example methoxybutanol, benzyl alcohol, ethyl diglycol or 1,2-propylene glycol. Any water-soluble organic solvents are here preferred.
The first essential ingredient a) in the hair treatment agents is at least one silicone. The silicone according to the invention is here selected from amino-functional silicones, dimethicones, dimethiconols, water-soluble silicones, cyclomethicones and any desired mixtures of these silicones. Amino-functional silicones may, for example, be described by the formula (Si-2)
M(RaObSiO(4-a-b)/2)x(RcSiO(4-c)/2)yM (Si-2)
wherein in the above formula
According to formula (Si-2), Z is an organic, amino-functional residue including at least one functional amino group. One possible formula for said Z is NH(CH2)zNH2, in which z is an integer greater than or equal to 1. Another possible formula for said Z is —NH(CH2)z(CH2)zzNH, in which both z and zz are mutually independently an integer greater than or equal to 1, wherein this structure comprises diamino ring structures, such as piperazinyl. Said Z is most preferably an —NHCH2CH2NH2 residue. Another possible formula for said Z is —N(CH2)z(CH2)zzNX2 or —NX2, in which each X of X2 is independently selected from the group consisting of hydrogen and alkyl groups with 1 to 12 carbon atoms, and zz is 0.
Q according to formula (Si-2) is most preferably a polar amino-functional residue of formula —CH2CH2CH2NHCH2CH2NH2.
In formula (Si-2), a assumes values in the range from 0 to 2, b assumes values in the range from 2 to 3, a+b is less than or equal to 3, and c is a number in the range from 1 to 3. Cationic silicone oils which are suitable according to the invention are for example the commercially obtainable products Dow Corning (DC) 929 Emulsion, DC 2-2078, DC 5-7113, SM-2059 (General Electric) and SLM-55067 (Wacker).
More preferred agents according to the invention are characterized in that they include at least one amino-functional silicone of formula (Si3-a)
in which m and n are numbers, the sum of which (m+n) amounts to between 1 and 2000, preferably between 50 and 150, wherein n preferably assumes values from 0 to 1999 and in particular from 49 to 149 and m preferably assumes values from 1 to 2000, in particular from 1 to 10.
According to the INCI declaration, these silicones are designated trimethylsilylamodimethicones and are obtainable for example under the name Q2-7224 (manufacturer: Dow Corning; a stabilized trimethylsilylamodimethicone).
Agents according to the invention which are more preferred are also those which include at least one amino-functional silicone of formula (Si-3b)
in which
According to the INCI declaration, these silicones are known as amodimethicones, or as functionalized amodimethicones, such as for example Bis(C13-15 Alkoxy) PG Amodimethicone (for example obtainable as the commercial product DC 8500 from Dow Corning).
Suitable diquaternary silicones are selected from compounds of general formula (Si3c))
[R1R2R3N+-A-SiR7R8—(O—SiR9R10)n—O—SiR11R12-A-N+R4R5R6]2X− (Si3c)
wherein the residues R1 to R6 mutually independently mean C1 to C22 alkyl residues which may include hydroxyl groups and wherein preferably at least one of the residues has at least 8 C atoms and the remaining residues have 1 to 4 C atoms, residues R7 to R12 are mutually independently identical or different and mean C1 to C10 alkyl or phenyl,
A means a divalent organic linking group,
n is a number from 0 to 200, preferably from 10 to 120, more preferably from 10 to 40, and X− is an anion.
The divalent linking group is preferably a C1 to C12 alkylene or alkoxyalkylene group which may be substituted with one or more hydroxyl groups. The group —(CH2)3—O—CH2—CH(OH)—CH2— is more preferred.
The anion X− may be a halide ion, an acetate, an organic carboxylate or a compound of general formula RSO3−, in which R has the meaning of C1 to C4 alkyl residues.
A preferred diquaternary silicone has the general formula (Si3d)
[RN+Me2-A-(SiMe2O)n—SiMe2-A-N+Me2R]2CH3COO− (Si3d),
wherein A is the group —(CH2)3—O—CH2—CH(OH)—CH2—,
R is an alkyl residue with at least 8 C atoms and n a number from 10 to 120.
Suitable silicone polymers with two terminal quaternary ammonium groups are known by the INCI name Quaternium-80. These are dimethylsiloxanes with two terminal trialkylammonium groups. Such diquaternary polydimethylsiloxanes are distributed by Evonik under the trade names Abil® Quat 3270, 3272 and 3474.
Hair treatment agents which are preferred according to the invention are characterized in that, relative to the weight thereof, they include 0.01 to 10 wt. %, preferably 0.01 to 8 wt. %, more preferably 0.1 to 7.5 wt. % and in particular 0.2 to 5 wt. % of amino-functional silicone(s) and/or diquaternary silicone.
Polyammonium-polysiloxane compounds are further silicones according to the invention with amino functions. The polyammonium-polysiloxane compounds may for example be obtained from GE Bayer Silicones under the trade name Baysilone®. The products named Baysilone TP 3911, SME 253 and SFE 839 are here preferred. It is particularly preferred to use Baysilone TP 3911 as an active component of the compositions according to the invention. The polyammonium-polysiloxane compounds are used in the compositions according to the invention in a quantity of 0.01 to 10 wt. %, preferably 0.01 to 7.5, more preferably 0.01 to 5.0 wt. %, particularly preferably of 0.05 to 2.5 wt. % in each case relative to the total composition.
EP 1887024 A1 describes novel cationic amino-functional silicones which in particular improve gloss in agents for conditioning surfaces, for example human hair. These cationic silicone polymers are distinguished in that they have a silicone backbone and at least one polyether moiety and furthermore at least one moiety with an ammonium structure. Examples of preferred cationic silicone polymers for the purposes of the present invention are, in addition to the compounds of the above-stated EP 1887024 A1, furthermore in particular the compounds with the NCI names. Silicone Quaternium-1, Silicone Quaternium-2, Silicone Quaternium-3, Silicone Quaternium-4, Silicone Quaternium-5, Silicone Quaternium-6, Silicone Quaternium-7, Silicone Quaternium-8, Silicone Quaternium-9, Silicone Quaternium-10, Silicone Quaternium-11, Silicone Quaternium-12, Silicone Quaternium-15, Silicone Quaternium-16, Silicone Quaternium-17, Silicone Quaternium-18, Silicone Quaternium-20, Silicone Quaternium-21, Silicone Quaternium-22 and Silicone Quaternium-2 Panthenol Succinate and Silicone Quaternium-16/Glycidyl Dimethicone Crosspolymer. Silicone Quaternium-22 is in particular most preferred. This raw material is distributed for example by Evonik under the trade name Abil® T-Quat 60.
A final aminosilicone which is particularly preferred according to the invention is of the following formula:
in which R1 denotes a methyl, ethyl, hydroxyl, methoxy or ethoxy group,
R2 denotes a straight-chain or branched C8 to C24 alkyl or alkylene residue, preferably a straight-chain or branched C9 to C22 alkyl or alkenyl residue, more preferably a straight-chain or branched C11 to C18 alkyl or alkenyl residue, highly preferably a corresponding alkyl residue,
n and m in each case denote integers of 1 to 1000 and
q in each case denotes an integer of 2 to 50, preferably 4 to 30, more preferably 4 to 18 and highly preferably of 4 to 12.
The molecular weight of such compounds amounts to 15,000 to 2,000,000, measured with a Brookfield rotational viscometer RV, spindle 5, at 20° C. The molar weight preferably amounts to 30,000 to 1,750,000 and more preferably 50,000 to 1,500,000. The nitrogen content of the silicones according to the invention amounts to 0.03 to 4.2 wt. %, preferably 0.1 to 2.8 wt. % and highly preferably 0.16 to 1.4 wt. %. Amino-functional cationic silicones according to the invention of the above formula may be purchased for example from Clariant. One product which is highly preferred according to the invention is commercially obtainable under the INCI name “Trideceth-9 Amodimethicone and Trideceth-12”.
The cationic amino-functional silicone polymers of the above-described formula are present in the compositions according to the invention in quantities of 0.01 to 5 wt. %, preferably in quantities of 0.05 to 5 wt. % and particularly preferably in quantities of 0.1 to 5 wt. %. The very best results are obtained with quantities of 0.1 to 2.5 wt. %, in each case relative to the total composition of the respective agent.
The cationic aminofunctional silicone polymers are present in the compositions according to the invention in quantities of 0.01 to 10 wt. %, preferably in quantities of 0.05 to 10 wt. % and particularly preferably in quantities of 0.1 to 7.5 wt. %. The very best results are obtained with quantities of 0.1 to 5 wt. %, in each case relative to the total composition of the respective agent.
The dimethicones according to the invention may be both linear and branched and cyclic or cyclic and branched. Linear dimethicones may be represented by the following structural formula (Si1):
(SiR13)—O—(SiR22—O—)x—(SiR13) (Si1)
Branched dimethicones may be represented by the structural formula (Si1.1):
The residues R1 and R2 mutually independently in each case denote hydrogen, a methyl residue, a C2 to C30 linear, saturated or unsaturated hydrocarbon residue, a phenyl residue and/or an aryl residue. The numbers x, y and z are integers and in each case mutually independently range from 0 to 50,000. The molar weights of the dimethicones are between 1000 D and 10000000 D. Viscosities are between 100 and 10000000 cPs measured at 25° C. with the assistance of a glass capillary viscometer using the Dow Corning Corporate Test Method CTM 0004 of 20 Jul. 1970. Preferred viscosities are between 1000 and 5000000 cPs, particularly preferred viscosities are between 10000 and 3000000 cPs. The most preferred range is between 50000 and 2000000 cPs. Viscosities around the range of approximately 60,000 cPs are highly preferred. Reference may be made by way of example to the product “Dow Corning 200, 60000 cSt”.
More preferred cosmetic or dermatological preparations according to the invention are characterized in that they include at least one silicone of formula (Si1.2)
(CH3)3Si—[O—Si(CH3)2]x—O—Si(CH3)3 (Si1.2),
in which x denotes a number from 0 to 100, preferably from 0 to 50, further preferably from 0 to 20 and in particular from 0 to 10.
The dimethicones (Si1) are present in the compositions according to the invention in quantities of 0.01 to 10 wt. %, preferably 0.01 to 8 wt. %, more preferably 0.1 to 7.5 wt. % and in particular 0.1 to 5 wt. % relative to the total composition.
Finally, silicone compounds are taken to mean dimethiconols (Si8). The dimethiconols according to the invention may be both linear and branched and cyclic or cyclic and branched. Linear dimethiconols may be represented by the following structural formula (Si8-I):
(SiOHR12)—O—(SiR22—O—)x—(SiOHR12) (Si8-I)
Branched dimethiconols may be represented by the structural formula (Si8-II):
The residues R1 and R2 mutually independently denote in each case hydrogen, a methyl residue, a C2 to C30 linear, saturated or unsaturated hydrocarbon residue, a phenyl residue and/or an aryl residue. The numbers x, y and z are integers and in each case mutually independently range from 0 to 50,000. The molar weights of the dimethiconols are between 1000 D and 10000000 D. Viscosities are between 100 and 10000000 cPs measured at 25° C. with the assistance of a glass capillary viscometer using the Dow Corning Corporate Test Method CTM 0004 of 20 Jul. 1970. Preferred viscosities are between 1000 and 5000000 cPs, particularly preferred viscosities are between 10000 and 3000000 cPs. The most preferred range is between 50000 and 2000000 cPs.
The following commercial products can be mentioned as examples of such products: Dow Corning 1-1254 Fluid, Dow Corning 2-9023 Fluid, Dow Corning 2-9026 Fluid, Abil OSW 5 (Degussa Care Specialties), Dow Corning 1401 Fluid, Dow Corning 1403 Fluid, Dow Corning 1501 Fluid, Dow Corning 1784 HVF Emulsion, Dow Corning 9546 Silicone Elastomer Blend, SM555, SM2725, SM2765, SM2785 (all above-stated from GE Silicones), Wacker-Belsil CM 1000, Wacker-Belsil CM 3092, Wacker-Belsil CM 5040, Wacker-Belsil DM 3096, Wacker-Belsil DM 3112 VP, Wacker-Belsil DM 8005 VP, Wacker-Belsil DM 60081 VP (all above-stated from Wacker-Chemie GmbH). The dimethiconols (Si8) are in the compositions according to the invention in quantities of 0.01 to 10 wt. %, preferably 0.01 to 8 wt. %, more preferably 0.1 to 7.5 wt. % and in particular 0.1 to 5 wt. % of dimethiconol relative to the composition.
The cyclic dimethicones designated according to INCI as cyclomethicones may also preferably be used according to the invention. Cosmetic or dermatological preparations which are preferred according to the invention are those which include at least one silicone of formula (Si-4)
in which x denotes a number from 3 to 200, preferably from 3 to 10, more preferably from 3 to 7 and in particular 3, 4, 5 or 6.
Agents which are likewise preferred according to the invention are those which are characterized in that they include at least one silicone of formula (Si-5)
R3Si—[O—SiR2]x—(CH2)n—[O—SiR2]y—O—SiR3 (Si-5),
in which R denotes identical or different residues from the group —H, phenyl, benzyl, —CH2—CH(CH3)Ph, C1-20 alkyl residues, preferably —CH3, —CH2CH3, —CH2CH2CH3, —CH(CH3)2, —CH2CH2CH2H3, —CH2CH(CH3)2, —CH(CH3)CH2CH3, —C(CH3)3, x and y denote a number from 0 to 200, preferably from 0 to 10, more preferably from 0 to 7 and in particular 0, 1, 2, 3, 4, 5 or 6, and n denotes a number from 0 to 10, preferably from 1 to 8 and in particular 2, 3, 4, 5, 6.
Further silicones which may be present in the compositions according to the invention, in addition to the dimethicones, dimethiconols, amodimethicones and/or cyclomethicones according to the invention, are water-soluble silicones.
Corresponding hydrophilic silicones are selected, for example, from the compounds of formulae (Si-6) and/or (Si-7). Particularly preferred water-soluble silicone-based surfactants are selected from the group of dimethicone copolyols which are preferably alkoxylated, in particular polyethoxylated or polypropoxylated.
According to the invention, dimethicone copolyols are preferably taken to mean polyoxyalkylene-modified dimethylpolysiloxanes of the general formulae (Si-6) or (Si-7):
in which the residue R denotes a hydrogen atom, an alkyl group with 1 to 12 C atoms, an alkoxy group with 1 to 12 C atoms or a hydroxyl group, the residues R′ and R″ mean alkyl groups with 1 to 12 C atoms, x denotes an integer from 1 to 100, preferably from 20 to 30, y denotes an integer from 1 to 20, preferably from 2 to 10 and a and b denote integers from 0 to 50, preferably from 10 to 30.
Dimethicone copolyols which are more preferred for the purposes of the invention are for example the products commercially distributed under the trade name SILWET (Union Carbide Corporation) and DOW CORNING. Dimethicone copolyols which are more preferred according to the invention are Dow Corning 190 and Dow Corning 193.
The dimethicone copolyols are in the compositions according to the invention in quantities of 0.01 to 10 wt. %, preferably 0.01 to 8 wt. %, more preferably 0.1 to 7.5 wt. % and in particular 0.1 to 5 wt. % of dimethicone copolyol relative to the composition.
Although any silicones may be used with the active ingredient combination according to the invention, it has been found that their effect declines in the sequence amino-functional silicones, dimethicones comparable with dimethiconols, cyclomethicones and water-soluble silicones. When more than two silicones are used, combinations of amino-functional silicones with dimethicones and/or dimethiconols have been found to be the most effective in increasing the effect. The very best effects are obtained if the silicones used are in each case the previously described more preferred silicone compounds.
The second mandatory component b) of the active substance complex is an ionic complex consisting of an acidic protein hydrolysate and a basic fatty acid amidoamine. In the present invention, an acidic protein hydrolysate is preferably taken to mean a plant protein hydrolysate. The protein hydrolysate moiety may, of course, also originate from any desired protein source. Plant protein hydrolysates such as soy, almond, pea, moringa, potato and wheat protein hydrolysates are preferred. Collagen hydrolysates from fish or seaweed and protein hydrolysates from mussels or pearl hydrolysates are likewise included according to the invention. It is, however, essential for the present invention for the proportion of acidic amino acids in the hydrolysate to amount to at least 10 wt. %, preferably 20 wt. %, more preferably 30 wt. % and highly preferably 40 wt. %. Protein hydrolysates which meet this condition form the ionic complexes according to the invention of an acidic protein hydrolysate and a basic fatty acid amidoamine of the present invention. Protein hydrolysates based on elastin, collagen, keratin, silk and milk protein are also possible, although not preferred, according to the invention.
Possible fatty acid amidoamines are any fatty acid amidoamine with a chain length of 8 to 40 carbon atoms in the chain. The fatty acid amidoamines may here be saturated or unsaturated, straight-chain or branched. The fatty acid amidoamines according to the invention are preferably of the following structure:
R1—NR2—(CH2)m—NR3R4R5,
in which R1 denotes a linear or branched, saturated or unsaturated acyl residue with 8 to 40 C atoms in the chain, R2 denotes a C1 to C4 alkyl residue or hydrogen, R3, R4 and R5 mutually independently denote hydrogen, a methyl residue or a C2 to C4 alkyl residue, n denotes an integer selected from 1, 2, 3, 4 or 5. More preferably, R2 means a methyl or ethyl residue, n=2 and R3=R4=methyl or ethyl and R5 denotes hydrogen. R1 preferably denotes one of the residues caprinoyl, lauroyl, myristoyl, palmitoyl, stearoyl, oleoyl, linoloyl, arachinoyl, cetyloyl, behenoyl, eicosanoyl and/or 18-methyleicosanoyl.
No anion is shown in the structure represented above. This anion is formed by an acidic group of the protein hydrolysate. Since the acidic protein hydrolysates according to the invention may comprise a plurality of acidic groups, a plurality of the fatty acid amidoamine structures represented above are accordingly also ionically attached to the acidic groups.
The carboxy-terminal end of the acidic protein hydrolysates forms an ionic complex with the cationic or cationizable C8 to C40 fatty acid amidoamine. Examples of such compounds under the INCI name Cetearamidoethyl diethonium hydrolyzed protein based on wheat or rice are commercially obtainable under the names Vegetamid® 18MEA R (Cetearamidoethyl Diethonium Hydrolyzed Rice) or Vegetamid® 18MEA G (Cetearamidoethyl Diethonium Hydrolyzed Wheat) from Seiwa Kasei.
The ionic complexes according to the invention of an acidic protein hydrolysate and a fatty acid amidoamine are present in the compositions according to the invention in a quantity of 0.01 to 10.0 wt. %, preferably of 0.01 to 7.5 wt. %, more preferably of 0.1 to 5.0 wt. % relative to the total composition.
In a more preferred embodiment of the present invention, selected quaternary ammonium compounds are furthermore preferably used with the mandatory ingredients already described above.
Quaternary ammonium compounds are in principle monomeric cationic or amphoteric ammonium compounds, monomeric amines, aminoamides, polymeric cationic ammonium compounds and polymeric amphoteric ammonium compounds. Among the numerous possible quaternary ammonium compounds, the following groups have proven particularly suitable and are in each case individually used in a quantity of 0.1 to 15.0 wt. %. Neither more nor less than this quantity is used even if a mixture of different compounds of quaternary ammonium compounds is used.
Cationic surfactants of formula (Tkat1) form the first group of cationic surfactants.
In the formula (Tkat1), R1, R2, R3 and R4 in each case mutually independently denote hydrogen, a methyl group, a phenyl group, a benzyl group, a saturated, branched or unbranched alkyl residue with a chain length of 8 to 30 carbon atoms, which may optionally be substituted with one or more hydroxyl groups. A denotes a physiologically acceptable anion, for example halides such as chloride or bromide and methosulfates.
Examples of compounds of formula (Tkat1) are lauryltrimethylammonium chloride, cetyltrimethylammonium chloride, cetyltrimethylammonium bromide, cetyltrimethylammonium methosulfate, dicetyldimethylammonium chloride, tricetylmethylammonium chloride, stearyltrimethylammonium chloride, distearyldimethylammonium chloride, lauryldimethylbenzylammonium chloride, behenyltrimethylammonium chloride, behenyltrimethylammonium bromide, behenyltrimethylammonium methosulfate.
Esterquats according to formula (Tkat2) form a preferred group.
The residues R1, R2 and R3 are here in each case mutually independent and may be identical or different. The residues R′, R2 and R3 mean:
Further compounds of formula (Tkat1-2) which are more preferred according to the invention belong to formula (Tkat2.1), the cationic betaine esters.
The meaning of R8 corresponds to that of R7.
More preferred esterquats are those with the trade names Armocare® VGH-70, and Dehyquart® F-75, Dehyquart® L80, Stepantex® VS 90 and Akypoquat® 131.
In preferred agents according to the invention, cationic surfactants of formula (bI) are used within relatively narrow quantity ranges, such that preferred hair treatment agents according to the invention are characterized in that they include 0.1 to 15 wt. %, preferably 0.5 to 10 wt. %, further preferably 1 to 10 wt. %, still more preferably 1.5 to 10 wt. % and in particular 2 to 5 wt. % of at least one compound of general formula (I).
in which
In particular when one of the compounds of formula (I) as previously described is used, it has been found that the conditioning effects of the agents according to the invention can be further increased and in particular the stability of the agents further improved if, in addition to the compound(s) of formula (I), the agents include specific acylated diamines.
Hair treatment agents which are preferred according to the invention are therefore characterized in that they additionally include 0.1 to 10 wt. % of at least one compound of formula (II)
in which x denotes 18, 19, 20, 21, 22, 23 or 24.
Compounds of formula (II) with n=20 are here more preferred. Highly preferred agents according to the invention are distinguished in that they include a compound of formula (I) always in conjunction with a compound of general formula (II).
A further group are quaternary imidazoline compounds. The formula (Tkat2) illustrated below shows the structure of these compounds.
The residues R mutually independently in each case denote a saturated or unsaturated, linear or branched hydrocarbon residue with a chain length of 8 to 30 carbon atoms. The preferred compounds of formula (Tkat2) in each case include the identical hydrocarbon residue for R. The chain length of the residues R preferably amounts to 12 to 21 carbon atoms. A denotes an anion as previously described. Examples which are particularly according to the invention are obtainable for example under the INCI names Quaternium-27, Quaternium-72, Quaternium-83 and Quaternium-91. Quaternium-91 is highly preferred according to the invention.
In a more preferred embodiment of the invention, the agents according to the invention furthermore include at least one amine and/or cationized amine, in particular an amidoamine and/or a cationized amidoamine with the following structural formulae:
R1—NH—(CH2)n—N+R2R3R4A (Tkat3)
in which R1 means an acyl or alkyl residue with 6 to 30 C atoms which may be branched or unbranched, saturated or unsaturated, and wherein the acyl residue and/or the alkyl residue may include at least one OH group, and
R2, R3 and R4 in each case mutually independently mean
A preferred composition is one in which the amine and/or the quaternized amine according to general formula (Tkat3) is an amidoamine and/or a quaternized amidoamine, in which R1 means a branched or unbranched, saturated or unsaturated acyl residue with 6 to 30 C atoms which may include at least one OH group. A fatty acid residue obtained from oils and waxes, in particular from natural oils and waxes, is here preferred. Examples thereof which may be considered are lanolin, beeswax or candelilla wax.
Preferred amidoamines and/or quaternized amidoamines are also those in which R2, R3 and/or R4 in formula (Tkat3) mean a residue according to general formula CH2CH2OR5, in which R5 may have the meaning of alkyl residues with 1 to 4 carbon atoms, hydroxyethyl or hydrogen. The preferred size of n in general formula (Tkat8) is an integer between 2 and 5.
The alkylamidoamines may both be present as such and be converted into a quaternary compound in the composition by protonation in an appropriately acidic solution. Cationic alkylamidoamines are preferred according to the invention.
Examples of such commercial products according to the invention are Witcamine® 100, Incromine® BB, Mackine® 401 and other Mackine® grades, Adogen® S18V, and, as permanently cationic aminoamines: Rewoquat® RTM 50, Empigen® CSC, Swanol® Lanoquat DES-50, Rewoquat® UTM 50, Schercoquat® BAS, Lexquat® AMG-BEO, or Incroquat® Behenyl HE.
A further fatty acid amide according to the invention is of general formula (I).
in which R1, R2 and R3 mutually independently denote a linear branched or unbranched C6 to C30, preferably C8 to C24, more preferably C12 to C22 and highly preferably C12 to C18 alkyl or alkenyl group. R1 to R3 preferably denote capryl, caprylyl, octyl, nonyl, decanyl, lauryl, myristyl, cetyl, stearyl, isostearyl, oleyl, behenyl or arachidyl. Furthermore, more preferably R2 equals R3 and highly preferably R1 equals R2 equals R3. The letters n and m mutually independently denote integers from 1 to 10, preferably 2 to 6 and highly preferably for 2, 3 and/or 4, wherein highly preferably n=m. Highly preferably, R1 equals R2 equals R3 and is selected from capryl, caprylyl, octyl, nonyl, decanyl, lauryl, myristyl, cetyl, stearyl, isostearyl, oleyl, behenyl or arachidyl and n=m=2. Most preferably R1=R2=R3 and is selected from lauryl, myristyl, cetyl, stearyl, isostearyl, oleyl, behenyl or arachidyl, of which cetyl, stearyl, isostearyl, oleyl or behenyl are more preferred and n=m=2. The most preferred compound of formula (I) is that having the INCI name Bis-Ethyl(isostearylimidazoline)Isostearamide. The latter compound is commercially obtainable from Croda under the trade name Keradyn® HH.
The above-stated cationic surfactants may be used individually or in any desired combinations with one another, wherein quantities of between 0.01 and 10 wt. %, preferably quantities of 0.01 to 7.5 wt. % and particularly preferably quantities of 0.1 to 5.0 wt. % are present. The very best results are here obtained with quantities of 0.1 to 3.0 wt. % in each case relative to the total composition of the respective agent.
Further quaternary ammonium compounds are cationic and amphoteric polymers.
The cationic and/or amphoteric polymers may be homo- or copolymers or polymers based on natural polymers, wherein the quaternary nitrogen groups are present either in the polymer chain or preferably as substituents on one or more of the monomers. Monomers including ammonium groups may be copolymerized with non-cationic monomers. Suitable cationic monomers are unsaturated, free-radically polymerizable compounds which bear at least one cationic group, in particular ammonium-substituted vinyl monomers such as for example trialkylmethacryloxyalkylammonium, trialkylacryloxyalkylammonium, dialkyldiallylammonium and quaternary vinylammonium monomers with cyclic, cationic nitrogen-containing groups such as pyridinium, imidazolinium or quaternary pyrrolidones, for example alkylvinylimidazolium, alkylvinylpyridinium or alkylvinylpyrrolidone salts. The alkyl groups of these monomers are preferably lower alkyl groups such as for example C1 to C7 alkyl groups, more preferably C1 to C3 alkyl groups.
Monomers including ammonium groups may be copolymerized with non-cationic monomers. Suitable comonomers are for example acrylamide, methacrylamide; alkyl- and dialkylacrylamide, alkyl- and dialkylmethacrylamide, alkyl acrylate, alkyl methacrylate, vinylcaprolactone, vinylcaprolactam, vinylpyrrolidone, vinyl esters, for example vinyl acetate, vinyl alcohol, propylene glycol or ethylene glycol, wherein the alkyl groups of these monomers are preferably C1 to C7 alkyl groups, more preferably C1 to C3 alkyl groups.
Among the numerous polymers of this kind, the following have proven to be particularly effective components of the active substance complex according to the invention:
homopolymers of general formula —{CH2—[CR1COO—(CH2)mN+R2R3R4]}nX−,
in which R1=—H or —CH3, R2, R3 and R4 are mutually independently selected from C1-4 alkyl, alkenyl or hydroxyalkyl groups, m=1, 2, 3 or 4, n is a natural number and X− is a physiologically acceptable organic or inorganic anion.
In the context of these polymers, those which are preferred according to the invention are those for which at least one of the following conditions applies: R1 denotes a methyl group, R2, R3 and R4 denote methyl groups, m has the value 2.
Physiologically acceptable counterions X− which may, for example, be considered are halide ions, sulfate ions, phosphate ions, methosulfate ions and organic ions such as lactate, citrate, tartrate and acetate ions. Methosulfates and halide ions, in particular chloride, are preferred.
Suitable cationic polymers are for example copolymers according to formula (Copo) which are present in the hair treatment agents according to the invention preferably in a quantity, relative to the weight thereof, of 0.001 to 5 wt. %, preferably 0.0025 to 2.5 wt. %, more preferably 0.005 to 1 wt. %, further preferably 0.0075 to 0.75 wt. % and in particular 0.01 to 0.5 wt. %.
in which:
x+y+z=Q
Irrespective of which of the preferred copolymers of formula (Copo) is used, preferred hair treatment agents according to the invention are those which are characterized in that the ratio of (y:z) amounts to 4:1 to 1:2, preferably 4:1 to 1:1.
Irrespective of which copolymers are used in the agents according to the invention, preferred hair treatment agents according to the invention are those which the copolymer has a molar mass of 10000 to 20 million gmol−1, preferably of 100000 to 10 million gmol−1, further preferably of 500000 to 5 million gmol−1 and in particular of 1.1 million to 2.2 million gmol−1.
One highly preferred copolymer which is of the above-described structure is commercially obtainable under the name Polyquaternium-74.
One particularly suitable homopolymer is poly(methacryloyloxyethyltrimethylammonium chloride), which may if desired be crosslinked, with the INCI name Polyquaternium-37. Such products are commercially obtainable for example under the names Rheocare® CTH (Cosmetic Rheologies) and Synthalen® CR (3V Sigma).
The homopolymer is preferably used in the form of a nonaqueous polymer dispersion. Such polymer dispersions are commercially obtainable under the names Salcare® SC 95 and Salcare® SC 96.
Suitable cationic polymers which are derived from natural polymers are cationic derivatives of polysaccharides, for example cationic derivatives of cellulose, starch or guar. Chitosan and chitosan derivatives are furthermore suitable. Cationic polysaccharides have the general formula G-O—B—N+RaRbRc A−
G is an anhydroglucose residue, for example starch or cellulose anhydroglucose;
B is a divalent linking group, for example alkylene, oxyalkylene, polyoxyalkylene or hydroxyalkylene;
Ra, Rb and Rc are mutually independently alkyl, aryl, alkylaryl, arylalkyl, alkoxyalkyl or alkoxyaryl in each case with up to 18 C atoms, wherein the total number of C atoms in Ra, Rb and Rc preferably amounts to at most 20;
A− is a conventional counteranion and is preferably chloride.
Cationic, thus quaternized, celluloses are commercially obtainable with different degrees of substitution, cationic charge densities, nitrogen contents and molecular weights. For example, Polyquaternium-67 is commercially offered for sale under the names Polymer® SL or Polymer® SK (Amerchol). A further highly preferred cellulose is offered for sale under the trade name Mirustyle® CP from Croda. This is a trimonium and cocodimonium hydroxyethylcellulose as a derivatized cellulose with the INCI name Polyquaternium-72. Polyquaternium-72 may be used both in solid form and already predissolved in aqueous solution.
Further cationic celluloses are Polymer JR® 400 (Amerchol, INCI name Polyquaternium-10) and Polymer Quatrisoft® LM-200 (Amerchol, INCI name Polyquaternium-24). Further commercial products are the compounds Celquat® H 100 and Celquat® L 200. More preferred cationic celluloses are Polyquaternium-24, Polyquaternium-67 and Polyquaternium-72.
Suitable cationic guar derivatives are distributed under the trade name Jaguar® and have the INCI name Guar Hydroxypropyltrimonium Chloride. Particularly suitable cationic guar derivatives are furthermore also commercially obtainable from Hercules under the name N-Hance®. Further cationic guar derivatives are distributed by Cognis under the name Cosmedia®. One preferred cationic guar derivative is the commercial product AquaCat® from Hercules. This raw material is an already predissolved cationic guar derivative. Cationic guar derivatives are preferred according to the invention.
One suitable chitosan is for example distributed by Kyowa Oil & Fat, Japan, under the tradename Flonac®. One preferred chitosan salt is chitosoniumpyrrolidone carboxylate, which is for example distributed by Amerchol, USA, under the name Kytamer® PC. Further chitosan derivatives are readily commercially obtainable under the trade names Hydagen® CMF, Hydagen® HCMF and Chitolam® NB/101.
A further group of polymers which may excellently be used according to the invention are polymers based on glucose. The following figure shows one such cationic alkyl oligoglucoside.
In the formula shown above, the residues R mutually independently denote a linear or branched C6 to C30 alkyl residue, a linear or branched C6-C30 alkenyl residue; the residue R preferably denotes a residue R selected from: lauryl, myristyl, cetyl, stearyl, oleyl, behenyl or arachidyl.
The residues R1 mutually independently denote a linear or branched C6 to C30 alkyl residue, a linear or branched C6 to C30 alkenyl residue; the residue R preferably denotes a residue selected from: butyl, capryl, caprylyl, octyl, nonyl, decanyl, lauryl, myristyl, cetyl, stearyl, oleyl, behenyl or arachidyl. The residues R1 are more preferably identical. The residues R1 are still more preferably selected from technical mixtures of the fatty alcohol cuts from C6/C8 fatty alcohols, C8/C10 fatty alcohols, C10/C12 fatty alcohols, C12/C14 fatty alcohols, C12/C18 fatty alcohols, while those technical fatty alcohol cuts which are of plant origin are highly preferred. The counterion to the cationic charge is a physiologically acceptable anion, for example halide, methosulfate, phosphate, citrate, tartrate, etc. The counterion is preferably a halide, such as fluoride, chloride or bromide, or methosulfate. The anion is highly preferably chloride.
More preferred examples of cationic alkyl oligoglucosides are the compounds with the INCI names Polyquaternium-77, Polyquaternium-78, Polyquaternium-79, Polyquaternium-80, Polyquaternium-81 and Polyquaternium-82. Highly preferred cationic alkyl oligoglucosides are those with the names Polyquaternium-77, Polyquaternium-81 and Polyquaternium-82.
Such compounds may for example be purchased under the name Poly Suga® Quat from Colonial Chemical Inc.
The cationic alkyl oligoglucosides are used in a total quantity of 0.01 to 10.0 wt. %, preferably of 0.05 to 5.0 wt. %, still more preferably of 0.1 to 3.0 wt. % and highly preferably in quantities of 0.2 to 2.0 wt. % in each case relative to the total weight of the composition. It goes without saying that a plurality of mixtures of cationic alkyl oligoglucosides may also be used according to the invention. It is preferred in this case, for one long-chain and one short-chain cationic alkyl oligoglucoside to be used simultaneously.
A further preferred cationic polymer may be obtained on the basis of ethanolamine. The polymer is commercially obtainable under the name Polyquaternium-71.
This polymer may for example be purchased under the name Cola® Moist 300 P from Colonial Chemical Inc.
Polyquaternium-71 is used in a total quantity of 0.01 to 10.0 wt. %, preferably of 0.05 to 5.0 wt. %, still more preferably of 0.1 to 3.0 wt. % and highly preferably in quantities of 0.2 to 2.0 wt. % in each case relative to the total weight of the composition.
A cationic alkyl oligoglucoside as shown in the following figure may furthermore particularly preferentially be used.
In the formula shown above, the residue R2 denotes a linear or branched C6 to C30 alkyl residue, a linear or branched C6-C30 alkenyl residue; the residue R preferably denotes a residue R selected from: lauryl, myristyl, cetyl, stearyl, oleyl, behenyl or arachidyl.
The residue R1 mutually independently denotes a linear or branched C6 to C30 alkyl residue, a linear or branched C6 to C30 alkenyl residue; the residue R1 preferably denotes a residue selected from: butyl, capryl, caprylyl, octyl, nonyl, decanyl, lauryl, myristyl, cetyl, stearyl, oleyl, behenyl or arachidyl. The residue R1 is still more preferably selected from technical mixtures of the fatty alcohol cuts from C6/C8 fatty alcohols, C8/C10 fatty alcohols, C10/C12 fatty alcohols, C12/C14 fatty alcohols, C12/C18 fatty alcohols, while those technical fatty alcohol cuts which are of plant origin are highly preferred. The index n denotes a number between 1 and 20, preferably between 1 and 10, more preferably between 1 and 5 and highly preferably between 1 and 3. The counterion for the cationic charge, A−, is a physiologically acceptable anion, for example halide, methosulfate, phosphate, citrate, tartrate, etc. The counterion is preferably a halide, such as fluoride, chloride or bromide, or methosulfate. The anion is highly preferably chloride.
More preferred examples of the cationic alkyl oligoglucosides are the compounds with the INCI names Laurdimoniumhydroxypropyl Decylglucosides Chloride, Laurdimoniumhydroxypropyl Laurylglucosides Chloride, Stearyldimoniumhydroxypropyl Decylglucosides Chloride, Stearyldimoniumhydroxypropyl Laurylglucosides Chloride, Stearyldimoniumhydroxypropyl Laurylglucosides Chloride or Cocoglucosides Hydroxypropyltrimonium Chloride.
Such compounds may for example be purchased under the name Suga® Quat from Colonial Chemical Inc.
The cationic alkyl oligoglucosides are used in a total quantity of 0.01 to 10.0 wt. %, preferably of 0.05 to 5.0 wt. %, still more preferably of 0.1 to 3.0 wt. % and highly preferably in quantities of 0.2 to 2.0 wt. % in each case relative to the total weight of the composition. It goes without saying that a plurality of mixtures of cationic alkyl oligoglucosides may also be used according to the invention. It is preferred in this case for one long-chain and one short-chain cationic alkyl oligoglucoside to be used simultaneously.
One more preferred cationic polymer according to the invention is the copolymer of N-vinylpyrrolidone, N-vinylcaprolactam, N-(3-dimethylaminopropyl)methacrylamide and 3-(methacryloylamino)propyllauryldimethylammonium chloride (INCI name: Polyquaternium-69), which is sold for example under the trade name AquaStyle® 300 (28-32 wt. % active substance in ethanol/water mixture, molecular weight 350000) by ISP.
Further preferred cationic polymers are for example
Amphoteric polymers according to the invention are those polymers in which a cationic group is derived from at least one of the following monomers:
R1—CH═CR2—CO—Z—(CnH2n)—N(+)R2R3R4A(−) (Mono1)
R8—CH═CR9—COOH (Mono3)
More preferred polymers are those in which monomers of type (i) are used, in which R3, R4 and R5 are methyl groups, Z is an NH group and A(−) a halide, methoxysulfate or ethoxysulfate ion; acrylamidopropyltrimethylammonium chloride is a more preferred monomer (i). Acrylic acid is preferably used as monomer (ii) for the stated polymers.
More preferred amphoteric polymers are copolymers prepared from at least one monomer (Mono1) or (Mono2) with the monomer (Mono3), in particular copolymers prepared from monomers (Mono2) and (Mono3). Amphoteric polymers which are particularly preferably used according to the invention are copolymers of diallyldimethylammonium chloride and acrylic acid. These copolymers are distributed under the INCI name Polyquaternium-22, inter alia with the trade name Merquat® 280 (Nalco).
Apart from a monomer (Mono1) or (Mono2) and a monomer (Mono3), amphoteric polymers according to the invention may furthermore additionally include a monomer (Mono4)
in which R10 and R11 are mutually independently hydrogen or methyl groups and R12 denotes a hydrogen atom or a (C1 to C8) alkyl group.
Amphoteric polymers based on a comonomer (Mono4) which are particularly preferably used according to the invention are terpolymers of diallyldimethylammonium chloride, acrylamide and acrylic acid. These copolymers are distributed under the INCI name Polyquaternium-39, inter alia with the trade name Merquat® Plus 3330 (Nalco).
The amphoteric polymers may generally be used according to the invention both directly and in salt form, which is obtained by neutralization of the polymers, for example with an alkali metal hydroxide.
The above-stated cationic polymers may be used individually or in any desired combinations with one another, wherein quantities of between 0.01 and 10 wt. %, preferably quantities of 0.01 to 7.5 wt. % and particularly preferably quantities of 0.1 to 5.0 wt. % are present. The very best results are here obtained with quantities of 0.1 to 3.0 wt. % in each case relative to the total composition of the respective agent.
It goes without saying that, in addition to the active substance combination according to the invention, the hair treatment agents according to the invention also include further components conventional in cosmetic compositions. The selection of these components is generally determined by the intended use of the hair treatment agents. In the case of a shampoo, further surface-active substances will, for example, be present. In the case of hair masks, further cationic compounds and further conditioning substances will optionally be present.
A further highly preferred ingredient of the compositions according to the invention is a hydroxycarboxylic acid. It has surprisingly been found that in those cases in which a hydroxycarboxylic acid is added in addition to the ingredients according to the invention of claims 1 and 2, the compositions are distinctly more stable with regard to storage stability. Stability is in particular improved at relatively high contents of silicone oils.
Hydroxycarboxylic acids are carboxylic acids which comprise both at least one carboxy group and at least a hydroxyl group per molecule. In particular, hydroxycarboxylic acids include both “AHA” acids and β-hydroxycarboxylic acids. Another name for such hydroxy acids is fruit acid because the acids frequently occur in fruit. The hydroxycarboxylic acid according to the invention is in particular selected from glycolic acid, lactic acid, glyceric acid, malic acid, citric acid, isocitric acid, mandelic acid, tartronic acid, tartaric acid, vanillic acid, salicylic acid, mevalonic acid, β-hydroxybutyric acid, gallic acid or protocatechuic acid. The hydroxycarboxylic acid is more preferably selected from glycolic acid, lactic acid, glyceric acid, malic acid, citric acid, mandelic acid, tartaric acid, vanillic acid and salicylic acid. The hydroxycarboxylic acid is particularly preferably selected from glycolic acid, lactic acid, malic acid, citric acid, mandelic acid, tartaric acid and vanillic acid. The hydroxycarboxylic acid is highly preferably selected from malic acid, mandelic acid, tartaric acid and vanillic acid. Mixtures of hydroxycarboxylic acids may, of course, also be used.
The compositions according to the invention include the hydroxycarboxylic acids in a total quantity of 0.01 to 15.0 wt. %, in particular of 0.01 to 10.0 wt. %, preferably of 0.1 to 7.5 wt. % and highly preferably in a quantity of 0.1 to 5.0 wt. % in each case relative to the total composition.
A further ingredient which increases the effect of the active ingredient combination according to the invention is an oil body. These are for example particularly preferentially ester oils. Ester oils are defined as follows:
Ester oils should be taken to mean the esters of C6-C30 fatty acids with C2-C30 fatty alcohols. The monoesters of fatty acids with alcohols with 2 to 24 C atoms are preferred. Examples of fatty acid moieties used in the esters are caproic acid, caprylic acid, 2-ethylhexanoic acid, capric acid, lauric acid, isotridecanoic acid, myristic acid, palmitic acid, palmitoleic acid, stearic acid, isostearic acid, oleic acid, elaidic acid, petroselinic acid, linoleic acid, linolenic acid, elaeostearic acid, arachidic acid, gadoleic acid, behenic acid and erucic acid and the technical mixtures thereof. Examples of fatty alcohol moieties in the ester oils are isopropyl alcohol, caproic alcohol, caprylic alcohol, 2-ethylhexyl alcohol, capric alcohol, lauryl alcohol, isotridecyl alcohol, myristyl alcohol, cetyl alcohol, palmoleyl alcohol, stearyl alcohol, isostearyl alcohol, oleyl alcohol, elaidyl alcohol, petroselinyl alcohol, linolyl alcohol, linolenyl alcohol, elaeostearyl alcohol, arachyl alcohol, gadoleyl alcohol, behenyl alcohol, erucyl alcohol and brassidyl alcohol and the technical mixtures thereof. More preferred substances according to the invention are isopropyl myristate (Rilanit® IPM), isononanoic acid C16-18 alkyl esters (Cetiol® SN), 2-ethylhexyl palmitate (Cegesoft® 24), stearic acid 2-ethylhexyl ester (Cetiol® 868), cetyl oleate, glycerol tricaprylate, coconut fatty alcohol caprinate/caprylate (Cetiol® LC), n-butyl stearate, oleyl erucate (Cetiol® J 600), isopropyl palmitate (Rilanit® IPP), Oleyl Oleate (Cetiol®), lauric acid hexyl ester (Cetiol® A), di-n-butyl adipate (Cetiol® B), myristyl myristate (Cetiol® mm), Cetearyl Isononanoate (Cetiol® SN), oleic acid decyl ester (Cetiol® V).
The ester oils may, of course, also be alkoxylated with ethylene oxide, propylene oxide or mixtures of ethylene oxide and propylene oxide. Alkoxylation may here proceed not only on the fatty alcohol moiety and the fatty acid moiety but also on both moieties of the ester oils. It is, however, preferred according to the invention if the fatty alcohol was alkoxylated first and then esterified with fatty acid. Formula (D4-II) is a general representation of these compounds.
R1 here denotes a saturated or unsaturated, branched or unbranched, cyclic saturated or cyclic unsaturated acyl residue with 6 to 30 carbon atoms,
AO denotes ethylene oxide, propylene oxide or butylene oxide,
X denotes a number between 1 and 200, preferably 1 and 100, more preferably between 1 and 50, particularly preferably between 1 and 20, highly preferably between 1 and 10 and most preferably between 1 and 5,
R2 denotes a saturated or unsaturated, branched or unbranched, cyclic saturated or cyclic unsaturated alkyl, alkenyl, alkynyl, phenyl or benzyl residue with 6 to 30 carbon atoms. Examples of fatty acid moieties used as residue R1 in the esters are caproic acid, caprylic acid, 2-ethylhexanoic acid, capric acid, lauric acid, isotridecanoic acid, myristic acid, palmitic acid, palmitoleic acid, stearic acid, isostearic acid, oleic acid, elaidic acid, petroselinic acid, linoleic acid, linolenic acid, elaeostearic acid, arachidic acid, gadoleic acid, behenic acid and erucic acid and the technical mixtures thereof. Examples of fatty alcohol moieties as residue R2 in the ester oils are benzyl alcohol, isopropyl alcohol, caproic alcohol, caprylic alcohol, 2-ethylhexyl alcohol, capric alcohol, lauryl alcohol, isotridecyl alcohol, myristyl alcohol, cetyl alcohol, palmoleyl alcohol, stearyl alcohol, isostearyl alcohol, oleyl alcohol, elaidyl alcohol, petroselinyl alcohol, linolyl alcohol, linolenyl alcohol, elaeostearyl alcohol, arachyl alcohol, gadoleyl alcohol, behenyl alcohol, erucyl alcohol and brassidyl alcohol and the technical mixtures thereof. One ester oil which is more preferred according to the invention is for example obtainable under the INCI name PPG-3 Benzyl Ether Myristate.
Ester oils should furthermore be taken to be:
The ester oils are used in the agents according to the invention in a quantity of 0.01 to 20 wt. %, preferably 0.01 to 10.0 wt. %, more preferably 0.01 to 7.5 wt. %, highly preferably of 0.1 to 5.0 wt. %. It is, of course, also possible according to the invention to use a plurality of ester oils simultaneously.
Further oil bodies according to the invention are:
Natural oils which are used are for example amaranth seed oil, apricot kernel oil, argan oil, avocado oil, babassu oil, cottonseed oil, borage seed oil, camelina oil, thistle oil, peanut oil, pomegranate seed oil, grapefruit seed oil, hemp oil, hazelnut oil, elderberry seed oil, blackcurrant seed oil, jojoba oil, cocoa butter, linseed oil, macadamia nut oil, maize germ oil, almond oil, marula oil, evening primrose oil, olive oil, palm oil, rapeseed oil, rice oil, sea buckthorn fruit oil, sea buckthorn seed oil, sesame oil, shea butter, soy oil, sunflower oil, grapeseed oil, walnut oil or wild rose oil.
In many cases, the agents include at least one surfactant, wherein not only anionic but also in principle zwitterionic, ampholytic, nonionic and cationic surfactants are suitable. The surface-active substances are selected on the basis of the nature of the agent.
Anionic surfactants (Tanion) which are suitable in preparations according to the invention are any anionic surface-active substances suitable for use on the human body. Typical examples of anionic surfactants are:
R1(OCH2CH2)n—O—(PO—OX)—OR2,
R8OC—(OCH2CH2)x—OCH2—[CHO(CH2CH2O)yH]—CH2O(CH2CH2O)z—SO3X,
If the mild anionic surfactants include polyglycol ether chains, it is particularly preferable for them to have a narrow homolog distribution. Furthermore, in the case of mild anionic surfactants with polyglycol ether units, it is preferred for the number of glycol ether groups to amount to 1 to 20, preferably 2 to 15, more preferably 2 to 12. Particularly mild anionic surfactants with polyglycol ether groups without a narrow homolog distribution may for example also be obtained if, on the one hand, the number of polyglycol ether groups amounts to 4 to 12 and Zn or Mg ions are selected as the counterion. One example of these is the commercial product Texapon® ASV.
Particularly suitable zwitterionic surfactants are “betaines” such as N-alkyl-N,N-dimethylammonium glycinates, for example cocoalkyldimethylammonium glycinate, N-acylaminopropyl-N,N-dimethylammonium glycinates, for example cocoacylaminopropyldimethylammonium glycinate, and 2-alkyl-3-carboxymethyl-3-hydroxyethylimidazolines with in each case 8 to 18 C atoms in the alkyl or acyl group and cocoacylaminoethylhydroxyethylcarboxymethyl glycinate. One preferred zwitterionic surfactant is the fatty acid amide derivative known by the INCI name Cocamidopropyl Betaine.
Ampholytic surfactants (Tampho) are taken to mean those surface-active compounds which are capable of forming internal salts. Examples of suitable ampholytic surfactants are N-alkylglycines, N-alkylpropionic acids, N-alkylaminobutyric acids, N-alkyliminodipropionic acids, N-hydroxyethyl-N-alkylamidopropylglycines, N-alkyltaurines, N-alkylsarcosines, 2-alkylaminopropionic acids and alkylaminoacetic acids with in each case approximately 8 to 24 C atoms in the alkyl group. Typical examples of amphoteric or zwitterionic surfactants are alkylbetaines, alkylamidobetaines, aminopropionates, aminoglycinates, imidazolinium betaines and sulfobetaines.
More preferred ampholytic surfactants are N-cocoalkyl aminopropionate, cocoacylaminoethyl aminopropionate and C12-18 acyl sarcosine.
Nonionic surfactants (Tnio) are for example
R1CO—(OCH2CHR2)wOR3 (Tnio-1)
The surfactants (T) are used in quantities of 0.05-45 wt. %, preferably of 0.1-30 wt. % and particularly preferably of 0.5-25 wt. %, relative to the total agent used according to the invention.
Examples of emulsifiers which may be used according to the invention are:
The agents according to the invention preferably include the emulsifiers in quantities of 0.1-25 wt. %, in particular of 0.5-15 wt. %, relative to the total agent.
The compositions according to the invention particularly preferably include fatty substances (Fat) as a further active substance. Fatty substances (Fat) should be taken to mean fatty acids, fatty alcohols, natural and synthetic waxes, which may assume both solid form and liquid form in an aqueous dispersion, and natural and synthetic cosmetic oil components.
Fatty acids (Fatac) which may be used are linear and/or branched, saturated and/or unsaturated fatty acids with 6-30 carbon atoms. Fatty acids with 10-22 carbon atoms are preferred. Such substances which may, for example, be mentioned are isostearic acid, such as the commercial products Emersol® 871 and Emersol® 875, and isopalmitic acids such as the commercial product Edenor® IP 95, and any further fatty acids distributed under the trade name Edenor® (Cognis). Further typical examples of such fatty acids are caproic acid, caprylic acid, 2-ethylhexanoic acid, capric acid, lauric acid, isotridecanoic acid, myristic acid, palmitic acid, palmitoleic acid, stearic acid, isostearic acid, oleic acid, elaidic acid, petroselinic acid, linoleic acid, linolenic acid, elaeostearic acid, arachidic acid, gadoleic acid, behenic acid and erucic acid and the technical mixtures thereof. The fatty acid cuts obtainable from coconut oil or palm oil are conventionally more preferred; in general, it is more preferred to use stearic acid.
The quantity used here amounts to 0.1-15 wt. %, relative to the total agent. Preferably, the quantity amounts to 0.5-10 wt. %, wherein quantities of 1-5 wt. % are particularly advantageous.
Fatty alcohols (Fatal) which may be used are saturated, mono- or polyunsaturated, branched or unbranched fatty alcohols with C6-C30, preferably C10-C22 and particularly preferably C12-C22 carbon atoms. For the purposes of the invention, it is for example possible to use decanol, octanol, octenol, dodecenol, decenol, octadienol, dodecadienol, decadienol, oleyl alcohol, erucic alcohol, ricinol alcohol, stearyl alcohol, isostearyl alcohol, cetyl alcohol, lauryl alcohol, myristyl alcohol, arachidyl alcohol, caprylic alcohol, capric alcohol, linoleyl alcohol, linolenyl alcohol and behenyl alcohol, and the Guerbet alcohols thereof, wherein this list is intended to be of an exemplary and non-limiting nature. The fatty alcohols are, however, preferably derived from natural fatty acids, wherein the conventional starting point is isolation from the fatty acid esters by reduction. Fatty alcohol cuts which are a mixture of various fatty alcohols may likewise be used according to the invention. Such substances are commercially obtainable for example under the names Stenol®, for example Stenol® 1618 or Lanette®, for example Lanette® 0 or Lorol®, for example Lorol® C8, Lorol® C14, Lorol® C18, Lorol® C8-18, HD-Ocenol®, Crodacol®, for example Crodacol® CS, Novol®, Eutanol® G, Guerbitol® 16, Guerbitol® 18, Guerbitol® 20, Isofol® 12, Isofol® 16, Isofol® 24, Isofol® 36, Isocarb® 12, Isocarb® 16 or Isocarb® 24. Wool wax alcohols, as are for example commercially obtainable under the names Corona®, White Swan®, Coronet® or Fluilan®, may of course also be used according to the invention. The fatty alcohols are used in quantities of 0.1-30 wt. %, relative to the total preparation, preferably in quantities of 0.1-20 wt. %,
Natural or synthetic waxes (Fatwax) which may be used according to the invention are solid paraffins or isoparaffins, carnauba waxes, beeswaxes, candelilla waxes, ozokerites, ceresin, spermaceti, sunflower wax, fruit waxes such as for example apple wax or citrus wax, PE or PP microwaxes. Such waxes are obtainable for example through Kahl & Co., Trittau.
The quantity used amounts to 0.1-50 wt. % relative to the total agent, preferably 0.1-20 wt. % and more preferably 0.1-15 wt. % relative to the total agent. The total quantity of oil and fat components in the agents according to the invention conventionally amounts to 0.5-75 wt. %, relative to the total agent. Quantities of 0.5-35 wt. % are preferred according to the invention.
A further synergistic active substance according to the invention in the compositions according to the invention with the active substance complex according to the invention are protein hydrolysates and/or the derivatives thereof (P).
Protein hydrolysates of both plant and animal origin or marine or synthetic origin may be used according to the invention.
Animal protein hydrolysates are for example elastin, collagen, keratin, silk and milk protein hydrolysates which may also assume salt form. Such products are distributed for example under the trademarks Dehylan® (Cognis), Promois® (Interorgana), Collapuron® (Cognis), Nutrilan® (Cognis), Gelita-Sol® (Deutsche Gelatine Fabriken Stoess & Co), Lexein® (Inolex) and Kerasol® (Croda).
Further plant protein hydrolysates which are preferred according to the invention are for example soy, almond, pea, moringa, potato and wheat protein hydrolysates. Such products are obtainable for example under the trademarks Gluadin® (Cognis), DiaMin® (Diamalt), Lexein® (Inolex), Hydrosoy® (Croda), Hydrolupin® (Croda), Hydrosesame® (Croda), Hydrotritium® (Croda), Crotein® (Croda) and Puricare® LS 9658 from Laboratoires Sérobiologiques.
Further protein hydrolysates which are preferred according to the invention are of maritime origin. These include for example collagen hydrolysates from fish or seaweed and protein hydrolysates from mussels or pearl hydrolysates. Examples of pearl extracts according to the invention are the commercial products Pearl Protein Extract BG® or Crodarom® Pearl.
Cationized protein hydrolysates should furthermore be included among protein hydrolysates and the derivatives thereof, wherein the underlying protein hydrolysate may originate from animals, for example from collagen, milk or keratin, from plants, for example from wheat, maize, rice, potato, soy or almonds, from marine life forms, for example from fish collagen or seaweed, or biotechnologically obtained protein hydrolysates. Typical examples of the cationic protein hydrolysates and derivatives according to the invention which may be mentioned are those that are commercially obtainable and mentioned among the INCI names in the “International Cosmetic Ingredient Dictionary and Handbook”, (seventh edition 1997, The Cosmetic, Toiletry, and Fragrance Association 1101 17th Street, N.W., Suite 300, Washington, D.C. 20036-4702).
The protein hydrolysates (P) are included in the compositions in concentrations of 0.001 wt. % to 20 wt. %, preferably of 0.05 wt. % to 15 wt. % and particularly preferably in quantities of 0.05 wt. % to 5 wt. %.
A further preferred group of ingredients of the compositions according to the invention with the active substance complex according to the invention are vitamins, provitamins or vitamin precursors.
Vitamins, provitamins and vitamin precursors which are more preferred are those which are assigned to groups A, B, C, E, F and H.
The group of substances designated vitamin A includes retinol (vitamin A1) and 3,4-didehydroretinol (vitamin A2). β-Carotene is the provitamin of retinol. Examples of a vitamin A component which may be considered according the invention are vitamin A acid and the esters thereof, vitamin A aldehyde and vitamin A alcohol and the esters thereof such as the palmitate and the acetate. The agents according to the invention preferably include the vitamin A component in quantities of from 0.05-1 wt. %, relative to the total preparation.
The vitamin B group or the vitamin B complex includes, inter alia:
vitamin B1 (thiamin)
vitamin B2 (riboflavin)
vitamin B3. This designation is frequently used for the compounds nicotinic acid and nicotinamide (niacinamide). Nicotinamide is preferred according to the invention and is preferably present in the agents according to the invention in quantities of from 0.05 to 1 wt. %, relative to the total agent.
Vitamin B5 (pantothenic acid, panthenol and pantolactone). In the context of this group, panthenol and/or pantolactone are preferably used. Derivatives of panthenol which may be used according to the invention are in particular the esters and ethers of panthenol and cationically derivatized panthenols. Individual representatives are for example panthenol triacetate, panthenol monoethyl ether and the monoacetate thereof and cationic panthenol derivatives. Pantothenic acid is preferably used in the present invention as a derivative in the form of the more stable calcium salts and sodium salts (Ca pantothenate, Na pantothenate).
Vitamin B6 (pyridoxine as well as pyridoxamine and pyridoxal).
The stated compounds of the vitamin B type, in particular vitamin B3, B5 and B6, are preferably present in the agents according to the invention in quantities of from 0.05-10 wt. %, relative to the total agent. Quantities of 0.1-5 wt. % are more preferred.
Vitamin C (ascorbic acid). Vitamin C is preferably used in the agents according to the invention in quantities of from 0.1 to 3 wt. %, relative to the total agent. Use in the form of the palmitic acid ester, the glucosides or phosphates may be preferred. Use in combination with tocopherols may likewise be preferred.
Vitamin E (tocopherols, in particular α-tocopherol). Tocopherol and the derivatives thereof, which include in particular the esters such as the acetate, the nicotinate, the phosphate and the succinate, are preferably present in the agents according to the invention in quantities of from 0.05-1 wt. %, relative to the total agent.
Vitamin F. The term “vitamin F” is conventionally understood to mean essential fatty acids, in particular linoleic acid, linolenic acid and arachidonic acid.
Vitamin H. Vitamin H denotes the compound (3aS,4S,6aR)-2-oxohexahydrothienol[3,4-d]imidazole-4-valeric acid, which is now, however, known by the common name biotin. Biotin is present in the agents according to the invention preferably in quantities of from 0.0001 to 1.0 wt. %, in particular in quantities of from 0.001 to 0.01 wt. %.
The agents according to the invention preferably include vitamins, provitamins and vitamin precursors from the groups A, B, E and H. Panthenol, pantolactone, pyridoxine and the derivatives thereof and nicotinamide and biotin are more preferred.
One more preferred group of ingredients in the cosmetic compositions according to the invention are the betaines stated below: carnitine, carnitine tartrate, carnitine magnesium citrate, acetylcarnitine, betalains, 1,1-dimethylproline, choline, choline chloride, choline bitartrate, choline dihydrogencitrate and the compound N,N,N-trimethylglycine which is designated as a betaine in the literature.
Carnitine, histidine, choline and betaine are preferably used. L-Carnitine tartrate is used as active substance in a more preferred embodiment of the invention.
More preferred agents according to the invention are those which, relative to the weight thereof, include 0.0001 to 10.0 wt. %, preferably 0.0005 to 5.0 wt. %, more preferably 0.001 to 2.0 wt. % and in particular 0.001 to 1.0 wt. % of at least one of the above-stated betaines, in particular carnitine tartrate.
In a further embodiment which is preferred according to the invention, the compositions according to the invention include bioquinones. In the agents according to the invention, suitable bioquinones should be taken to mean one or more ubiquinone(s) and/or plastoquinone(s). Ubiquinones which are preferred according to the invention have the following formula:
Coenzyme Q-10 is here most preferred.
Preferred compositions according to the invention include purine and/or purine derivatives in relatively narrow quantity ranges. Cosmetic agents which are preferred according to the invention are here characterized in that, relative to the weight thereof, they include 0.001 to 2.5 wt. %, preferably 0.0025 to 1 wt. %, more preferably 0.005 to 0.5 wt. % and in particular 0.01 to 0.1 wt. % of purine(s) and/or purine derivative(s). Cosmetic agents which are preferred according to the invention are characterized in that they include purine, adenine, guanine, uric acid, hypoxanthine, 6-purinethiol, 6-thioguanine, xanthine, caffeine, theobromine or theophylline. Caffeine is most preferred in hair cosmetic preparations.
In a further preferred embodiment of the present invention, the cosmetic agent includes ectoine ((S)-2-methyl-1,4,5,6-tetrahydro-4-pyrimidinecarboxylic acid).
Agents which are more preferred according to the invention are those which, relative to the weight thereof, include 0.00001 to 10.0 wt. %, preferably 0.0001 to 5.0 wt. % and in particular 0.001 to 3 wt. % of the active substances from the group which is formed by carnitine, coenzyme Q-10, ectoine, a vitamin of the B series, a purine and the derivatives thereof or physiologically acceptable salts.
One particularly preferred conditioning additive in the hair treatment agents according to the invention is taurine. Taurine is exclusively taken to mean 2-aminoethanesulfonic acid while a derivative is taken to mean the explicitly stated derivatives of taurine. The derivatives of taurine are taken to mean N-monomethyltaurine, N,N-dimethyltaurine, taurine lysylate, taurine tartrate, taurine omithate, lysyltaurine and ornithyltaurine.
More preferred agents according to the invention are those which, relative to the weight thereof, include 0.0001 to 10.0 wt. %, preferably 0.0005 to 5.0 wt. %, more preferably 0.001 to 2.0 wt. % and in particular 0.001 to 1.0 wt. % of taurine and/or a derivative of taurine.
The action of the compositions according to the invention may furthermore be increased by a 2-pyrrolidinone-5-carboxylic acid and the derivatives thereof (J). The sodium, potassium, calcium, magnesium or ammonium salts, in which, in addition to hydrogen, the ammonium ion bears one to three C1 to C4 alkyl groups, are preferred. The sodium salt is particularly preferred. The quantities used in the agents according to the invention amount to 0.05 to 10 wt. %, relative to the total agent, more preferably 0.1 to 5, and in particular 0.1 to 3 wt. %.
Thanks to the use of plant extracts as conditioning substances, the hair treatment agents according to the invention may have a formulation which is particularly close to nature while nevertheless being very effective in terms of their conditioning performance. It is optionally even possible to dispense with the preservatives which would otherwise be conventional. According to the invention, preference is above all given to extracts from green tea, oak bark, stinging nettle, witch hazel, hops, henna, chamomile, burdock root, horsetail, hawthorn, lime blossom, almond, aloe vera, pine needle, horse chestnut, sandalwood, juniper, coconut, mango, apricot, lime, wheat, kiwi fruit, melon, orange, grapefruit, sage, rosemary, birch, mallow, valerian, lady's smock, wild thyme, yarrow, thyme, melissa, restharrow, coltsfoot, marsh mallow, meristem, ginseng, coffee, cocoa, moringa, ginger root and ayurvedic plant extracts, such as for example Aegle marmelos (bilwa), Cyperus rotundus (nagar motha), Emblica officinalis (amalaki), Morida citrifolia (ashyuka), Tinospora cordifolia (guduchi), Santalum album (chandana), Crocus sativus (kumkuma), Cinnamonum zeylanicum and Nelumbo nucifera (kamala), sweet grasses such as wheat, barley, rye, oats, spelt, maize, the various varieties of millet (proso millet, African finger millet, foxtail millet as examples), sugar cane, ryegrass, meadow foxtail, oat grass, bentgrass, meadow fescue, moor grass, bamboo, cotton grass, fountain grasses, Andropogoneae (Imperata cylindrica also known as blady grass or cogon grass), buffalo grass, cordgrasses, dog's tooth grasses, lovegrasses, Cymbopogon (lemon grass), Oryzeae (rice), Zizania (wild rice), marram grass, steppe oat, softgrasses, quaking grasses, bluegrasses, couch grasses and Echinacea, in particular Echinacea purpurea (L.) Moench, all species of vine and pericarp of Litchi chinensis.
The plant extracts may be used according to the invention in both pure and dilute form. Where used in dilute form, they conventionally include approx. 2-80 wt. % of active substance and, as solvent, the extracting agent or extracting agent mixture used to isolate them.
In a further embodiment, the agents according to the invention should additionally include at least one UV light protection filter. UVB filters may be oil-soluble or water-soluble.
Oil-soluble substances which may be mentioned are, for example:
Typical UVA filters which may be considered are in particular derivatives of benzoylmethane, such as for example 1-(4′-tert.-butylphenyl)-3-(4′-methoxyphenyl)propane-1,3-dione or 1-phenyl-3-(4′-sopropylphenyl)propane-1,3-dione. The UVA and UVB filters may, of course, also be used in mixtures.
In addition to the stated soluble substances, insoluble pigments may be considered for this purpose, in particular finely dispersed metal oxides or salts, such as for example titanium dioxide, zinc oxide, iron oxide, aluminum oxide, cerium oxide, zirconium oxide, silicates (talcum), barium sulfate and zinc stearate. These pigments are preferred according to the invention, in particular as a component of a mixture of a plurality of structurally different UV filters. The particles should here have an average diameter of less than 100 nm, preferably between 5 and 50 nm and in particular between 15 and 30 nm. They may have a spherical shape, but such particles having a shape which is ellipsoidal or differs in another way from spherical may also be used.
The total quantity of UV filter substances in the compositions according to the invention amounts, in each case relative to the total composition, to 0.01 to 15.0 wt. %, preferably 0.01 to 10.0 wt. %, more preferably 0.1 to 10.0 wt. %, more preferably 0.2 to 10.0 wt. % and highly preferably 0.3 to 10.0 wt. %.
It may occasionally be necessary to use anionic polymers. Examples of anionic monomers of which such polymers may consist are acrylic acid, methacrylic acid, crotonic acid, maleic anhydride and 2-acrylamido-2-methylpropanesulfonic acid. In this case, the acidic groups may be present wholly or in part as a sodium, potassium, ammonium, mono- or triethanolammonium salt. 2-Acrylamido-2-methylpropanesulfonic acid and acrylic acid are preferred monomers.
Anionic polymers which have proven very particularly effective are those which include as sole or co-monomer 2-acrylamido-2-methylpropanesulfonic acid, wherein the sulfonic acid group may be present wholly or in part as a sodium, potassium, ammonium, mono- or triethanolammonium salt.
The homopolymer of 2-acrylamido-2-methylpropanesulfonic acid is more preferred, and is commercially obtainable for example under the name Rheothik®11-80.
Preferred nonionogenic monomers are acrylamide, methacrylamide, acrylic acid esters, methacrylic acid esters, vinylpyrrolidone, vinyl ethers and vinyl esters.
Preferred anionic copolymers are acrylic acid-acrylamide copolymers and in particular polyacrylamide copolymers with monomers including sulfonic acid groups. Such a polymer is present in the commercial product Sepigel®305 from SEPPIC.
Anionic homopolymers which are likewise preferred are uncrosslinked and crosslinked polyacrylic acids. In this case, allyl ethers of pentaerythritol, of sucrose and of propylene may be preferred crosslinking agents. Such compounds are commercially obtainable for example under the trademark Carbopol®.
Copolymers of maleic anhydride and methyl vinyl ether, in particular those comprising crosslinks, are also color-preserving polymers. A maleic acid-methyl vinyl ether copolymer crosslinked with 1,9-decadiene is commercially obtainable under the name Stabileze® QM.
The anionic polymers are present in the agents according to the invention preferably in quantities of from 0.05 to 10 wt. %, relative to the total agent. Quantities of 0.1 to 5 wt. % are more preferred.
In a further embodiment, the agents according to the invention may include nonionogenic polymers.
Suitable nonionogenic polymers are for example:
The nonionic polymers are present in the compositions according to the invention preferably in quantities of from 0.05 to 10 wt. %, relative to the total agent. Quantities of 0.1 to 5 wt. % are more preferred.
The cosmetic agents may moreover include further active substances, auxiliary substances and additives, such as for example
With regard to further optional components and the quantities of these components used, reference is explicitly made to the relevant handbooks known to a person skilled in the art.
The invention secondly provides a method for hair treatment, in which the hair treatment agent according to claim 1 is applied onto the hair and, after a period of exposure, rinsed out of the hair.
The period of exposure preferably amounts to a few seconds to 100 minutes, more preferably to 1 to 50 minutes and particularly preferably to 1 to 30 minutes.
A method in which the cosmetic agent according to claim 1 is applied onto the hair and remains there is furthermore according to the invention. According to the invention, “remain on the hair” is taken to mean that the agent is not rinsed back out of the hair immediately after the use of thereof. Instead, the agent remains on the hair in this case for more than 100 minutes up to until the next time the hair is washed.
The following examples are intended to explain the subject matter of the present invention but without limiting it.
Unless otherwise stated, all quantities are stated in parts by weight. The following formulations were prepared using known production methods.
Hair Conditioner:
The pH value of all formulations was adjusted to 2 to 4.
Hair Mask:
The pH value of all formulations was adjusted to 2 to 4.
Hair Shampoo:
The pH value of all the formulations was adjusted to 4.5 to 5.8.
Thickeners which may be used are any thickeners or thickener systems known to a person skilled in the art in surfactant systems. For example, cellulose ethers, xanthan gums, hydroxyethylcelluloses, Laureth-2 and Laureth-3, and for example the products known by the trade names Antil® or Crothix® are in each case used individually or in mixtures with one another in the above-stated formulations.
While at least one exemplary embodiment has been presented in the foregoing detailed description of the invention, it should be appreciated that a vast number of variations exist. It should also be appreciated that the exemplary embodiment or exemplary embodiments are only examples, and are not intended to limit the scope, applicability, or configuration of the invention in any way. Rather, the foregoing detailed description will provide those skilled in the art with a convenient road map for implementing an exemplary embodiment of the invention, it being understood that various changes may be made in the function and arrangement of elements described in an exemplary embodiment without departing from the scope of the invention as set forth in the appended claims and their legal equivalents.
| Number | Date | Country | Kind |
|---|---|---|---|
| 10 2012 214 141.3 | Aug 2012 | DE | national |
| Number | Date | Country | |
|---|---|---|---|
| Parent | PCT/EP2013/064213 | Jul 2013 | US |
| Child | 14614566 | US |
